--(www.USEquityNews.com)-- 06/09/2008 - Healthcare industry alert provided by U.S. Equity News. Healthcare industry alert provided by U.S. Equity News. TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that the company has executed an exclusive option agreement with The University of British Columbia (UBC) for three follow on technologies related to the original TAP-technology acquired by the company from UBC on May 31, 2007. "We are very pleased to be able to continue to strengthen our pipeline of technologies and our IP position around our key TAP technologies," said Denis Corin, CEO of TapImmune Inc. For more information, please visit www.stocksjournal.com.
Biopure Corporation (Nasdaq: BPUR) today announced that it has sent an open letter to the editors of the Journal of the American Medical Association (JAMA). The letter asks for a retraction of the meta-analysis and the accompanying editorial that appeared on line on April 28, 2008 and in the later print edition, as well as an apology to the hemoglobin-based oxygen carrier (HBOC) field. The letter and Biopure's analysis have been posted at www.biopure.com.
Hologic, Inc. (Nasdaq: HOLX), of Bedford, Mass., announced today that it has signed a definitive agreement to acquire Third Wave Technologies, Inc. (Nasdaq: TWTI) for a purchase price of $11.25 per share, or approximately $580 million in value, representing an approximately 24% premium to Third Wave's average trading price over the last three months. The Boards of Directors of both companies unanimously approved the transaction in which Hologic is to acquire 100% of Third Wave's stock in a cash tender offer to be followed by a merger to acquire any untendered shares. The transaction, completion of which is anticipated in the third calendar quarter of 2008, is expected to be modestly dilutive to Hologic's adjusted earnings per share in the first full year after closing, and increasingly accretive thereafter.
Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that a multicenter Phase 3 study of Lymphoseek(R) has been initiated in patients with either breast cancer or melanoma. The Phase 3 study will evaluate the efficacy of Lymphoseek to identify lymph nodes that may be predictive of determining whether a patient's cancer has spread into the lymphatic system. The Phase 3 study has been registered on the national clinical trials website www.clinicaltrials.gov.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
